Dendrimers for Drug Delivery: Where Do We Stand in 2023?
Conflicts of Interest
References
- Arbez-Gindre, C.; Steele, B.R.; Micha-Screttas, M. Dendrimers in Alzheimer’s Disease: Recent Approaches in Multi-Targeting Strategies. Pharmaceutics 2023, 15, 898. [Google Scholar] [CrossRef] [PubMed]
- Kisakova, L.A.; Apartsin, E.K.; Nizolenko, L.F.; Karpenko, L.I. Dendrimer-Mediated Delivery of DNA and RNA Vaccines. Pharmaceutics 2023, 15, 1106. [Google Scholar] [CrossRef] [PubMed]
- Pricl, S. The Spicy Science of Dendrimers in the Realm of Cancer Nanomedicine: A Report from the COST Action CA17140 Nano2Clinic. Pharmaceutics 2023, 15, 2013. [Google Scholar] [CrossRef] [PubMed]
- Neugebauer, M.; Grundmann, C.E.; Lehnert, M.; von Stetten, F.; Früh, S.M.; Süss, R. Analyzing siRNA Concentration, Complexation and Stability in Cationic Dendriplexes by Stem-Loop Reverse Transcription-qPCR. Pharmaceutics 2022, 14, 1348. [Google Scholar] [CrossRef] [PubMed]
- Knauer, N.; Pashkina, E.; Aktanova, A.; Boeva, O.; Arkhipova, V.; Barkovskaya, M.; Meschaninova, M.; Karpus, A.; Majoral, J.-P.; Kozlov, V.; et al. Effects of Cationic Dendrimers and Their Complexes with microRNAs on Immunocompetent Cells. Pharmaceutics 2023, 15, 148. [Google Scholar] [CrossRef] [PubMed]
- Shiba, H.; Hirose, T.; Fu, Y.; Michigami, M.; Fujii, I.; Nakase, I.; Matsumoto, A.; Kojima, C. T Cell-Association of Carboxy-Terminal Dendrimers with Different Bound Numbers of Phenylalanine and Their Application to Drug Delivery. Pharmaceutics 2023, 15, 888. [Google Scholar] [CrossRef]
- Szota, M.; Jachimska, B. Effect of Alkaline Conditions on Forming an Effective G4.0 PAMAM Complex with Doxorubicin. Pharmaceutics 2023, 15, 875. [Google Scholar] [CrossRef] [PubMed]
- Hersh, J.; Yang, Y.-P.; Roberts, E.; Bilbao, D.; Tao, W.; Pollack, A.; Daunert, S.; Deo, S.K. Targeted Bioluminescent Imaging of Pancreatic Ductal Adenocarcinoma Using Nanocarrier-Complexed EGFR-Binding Affibody–Gaussia Luciferase Fusion Protein. Pharmaceutics 2023, 15, 1976. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Apartsin, E.K. Dendrimers for Drug Delivery: Where Do We Stand in 2023? Pharmaceutics 2023, 15, 2740. https://doi.org/10.3390/pharmaceutics15122740
Apartsin EK. Dendrimers for Drug Delivery: Where Do We Stand in 2023? Pharmaceutics. 2023; 15(12):2740. https://doi.org/10.3390/pharmaceutics15122740
Chicago/Turabian StyleApartsin, Evgeny K. 2023. "Dendrimers for Drug Delivery: Where Do We Stand in 2023?" Pharmaceutics 15, no. 12: 2740. https://doi.org/10.3390/pharmaceutics15122740
APA StyleApartsin, E. K. (2023). Dendrimers for Drug Delivery: Where Do We Stand in 2023? Pharmaceutics, 15(12), 2740. https://doi.org/10.3390/pharmaceutics15122740